Haplotipos HLA en familias chilenas con diabetes tipo 1

Pérez B., Francisco; Santos M., José L; Calvillán C., Marcelo; Carrasco Piña, Elena.
Rev. méd. Chile ; 126(12): 1455-63, dic. 1998. ilus, tab
Artículo en Español | LILACS | ID: lil-243742

Documentos relacionados

  1. Leveraging type 1 diabetes human genetic and genomic data in the T1D knowledge portal.
  2. TCR<sup>+</sup>/BCR<sup>+</sup> dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes.
  3. MHC-II heterozygosity limits type 1 diabetes susceptibility through negative selection.
  4. Th2 cell clonal expansion at diagnosis in human type 1 diabetes.
  5. Genome-wide aggregated trans-effects on risk of type 1 diabetes: A test of the "omnigenic" sparse effector hypothesis of complex trait genetics.
  6. Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".
  7. The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants.
  8. Epigenetic modifications in pancreas development, diabetes, and therapeutics.
  9. Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?
  10. Contribution of Retrotransposons to the Pathogenesis of Type 1 Diabetes and Challenges in Analysis Methods.